- Home
- GCTS vs ZURA Comparison
GCTS vs ZURA Comparison
Compare GCTS & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GCTS
- ZURA
- Stock Information
- Founded
- GCTS 1998
- ZURA 2022
- Country
- GCTS United States
- ZURA United States
- Employees
- GCTS N/A
- ZURA N/A
- Industry
- GCTS Blank Checks
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GCTS Finance
- ZURA Health Care
- Exchange
- GCTS Nasdaq
- ZURA Nasdaq
- Market Cap
- GCTS 82.5M
- ZURA 69.9M
- IPO Year
- GCTS N/A
- ZURA N/A
- Fundamental
- Price
- GCTS $1.26
- ZURA $1.66
- Analyst Decision
- GCTS Strong Buy
- ZURA Strong Buy
- Analyst Count
- GCTS 1
- ZURA 9
- Target Price
- GCTS $5.00
- ZURA $14.00
- AVG Volume (30 Days)
- GCTS 206.6K
- ZURA 369.7K
- Earning Date
- GCTS 08-12-2025
- ZURA 08-14-2025
- Dividend Yield
- GCTS N/A
- ZURA N/A
- EPS Growth
- GCTS N/A
- ZURA N/A
- EPS
- GCTS N/A
- ZURA N/A
- Revenue
- GCTS $6,073,000.00
- ZURA N/A
- Revenue This Year
- GCTS $133.55
- ZURA N/A
- Revenue Next Year
- GCTS $347.37
- ZURA N/A
- P/E Ratio
- GCTS N/A
- ZURA N/A
- Revenue Growth
- GCTS N/A
- ZURA N/A
- 52 Week Low
- GCTS $0.90
- ZURA $0.97
- 52 Week High
- GCTS $3.84
- ZURA $5.07
- Technical
- Relative Strength Index (RSI)
- GCTS 40.91
- ZURA 58.91
- Support Level
- GCTS $1.21
- ZURA $1.44
- Resistance Level
- GCTS $1.45
- ZURA $1.52
- Average True Range (ATR)
- GCTS 0.11
- ZURA 0.13
- MACD
- GCTS -0.02
- ZURA 0.00
- Stochastic Oscillator
- GCTS 15.94
- ZURA 76.92
About GCTS GCT Semiconductor Holding Inc. Common Stock
GCT Semiconductor Holding Inc is a designer and supplier of 5G and 4G LTE semiconductor solutions. It enabled fast and reliable 4G LTE connectivity to numerous commercial devices such as CPEs, mobile hotspots, routers, M2M applications, and smartphones, etc. The system-on-chip solutions integrate radio frequency, baseband modem, and digital signal processing functions, therefore offering complete 4G and 5G platform solutions with small form factors, low power consumption, high performance, high reliability, and cost-effectiveness.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.